This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT01651117
First received: July 24, 2012
Last updated: May 25, 2017
Last verified: May 2017
July 24, 2012
May 25, 2017
September 1, 2012
April 8, 2018   (Final data collection date for primary outcome measure)
Change in Glucose Control [ Time Frame: Baseline, 6 months, and 12 months and for former mentees 18 months ]
Measured by change in HbA1c
Change in Glucose Control [ Time Frame: Baseline, 6 months, and 12 months ]
Measured by change in HbA1c
Complete list of historical versions of study NCT01651117 on ClinicalTrials.gov Archive Site
  • Blood Pressure [ Time Frame: Baseline, 6 months, 12 months and for former mentees 18 months ]
    Measured by change in Blood Pressure
  • Diabetes Quality of Life [ Time Frame: Baseline, 6 months, 12 months and for former mentees 18 months ]
    Diabetes Distress Scale
  • Depression Symptoms [ Time Frame: Baseline, 6 months, and 12 months and for former mentees 18 months ]
    As measured by the Patient Health Questionnaire-2
  • Direct LDL blood levels [ Time Frame: Baseline, 6 months, and 12 months and for former mentees 18 months ]
    Measured by change in Direct LDL blood levels
  • Blood Pressure [ Time Frame: Baseline, 6 months, 12 months ]
  • Diabetes Quality of Life [ Time Frame: Baseline, 6 months, 12 months ]
    Diabetes Distress Scale
  • Depression Symptoms [ Time Frame: Baseline, 6 months, and 12 months ]
    As measured by the Patient Health Questionnaire-2
  • Direct LDL blood levels [ Time Frame: Baseline, 6 months, and 12 months ]
Not Provided
Not Provided
 
Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control
Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control
The purpose of this study is to test the effectiveness of a peer mentor model in a mixed race population of poorly controlled diabetic Veterans. Also, the study aims to assess the effects of becoming a mentor on those who originally were mentees. It is expected that participants in the peer mentoring arms (Arm 2 and 3) will have improved glucose control regardless of race or ethnicity at the end of the intervention.

The primary objectives of this study are: (1) test the long-term effectiveness of a peer mentor model on improving glucose control, blood pressure, LDL levels, diabetes mellitus quality of life, and depression scores in a mixed race population of poorly controlled diabetic Veterans; (2) test the effectiveness of using former peer mentees as peer mentors as a means of creating a self-sustaining program; and (3) and test the effects of becoming a mentor on those who were originally mentees given a growing literature that being a mentor is good for your health. Secondary objectives include: (1) in those randomized to being a mentee, explore mentor characteristics associated with improved HbA1c.

This study will be a prospective randomized controlled trial. Outcomes to be measured include glycosylated hemoglobin, blood pressure, direct LDL, diabetes quality of life and depression.

The trial has two phases. In phase one, patients with poorly controlled diabetes are randomized to usual care or receiving peer mentoring. In phase two, poorly controlled diabetics are randomized to usual care or receiving peer mentoring from former mentees. Former mentees from phase 1 are also randomized such that they will have a 50% chance of becoming a mentor.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Investigator
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
Behavioral: Peer Mentoring

Arm 2: Will receive peer mentoring from diabetic veterans who were once in poor control but are now in good control.

Arm 3: Will receive peer mentoring from former mentees

  • No Intervention: Usual Care
    Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
  • Experimental: Peer Mentoring
    Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
    Intervention: Behavioral: Peer Mentoring
  • Experimental: Peer Mentoring FFM (from former mentee)
    Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
    Intervention: Behavioral: Peer Mentoring
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
698
October 8, 2018
April 8, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Inclusion Criteria:

  • All participants must have a diagnosis of Type 2 diabetics.
  • Diabetes began after age 30
  • Mentees: Have an HbA1c > 8% on 2 different occasions in the course of 24 months, with at least one measure within 3 months of enrollment
  • Mentors for Phase 1: Had an HbA1c of > 8% in the past 3 years and an HbA1c < (or equal to) 7.5% within 3 months of enrollment
  • Mentors for Phase 2: Former mentee

Exclusion Criteria:

Exclusion Criteria:

  • Does not speak English
  • Unable to understand consents
  • Severe speech impediment
  • over the age of 75
Sexes Eligible for Study: All
30 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01651117
IIR 12-407
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Plan to Share IPD: Yes
Plan Description: Data will be made available upon request of the PI
VA Office of Research and Development
VA Office of Research and Development
Not Provided
Principal Investigator: Judith A. Long, MD Philadelphia VA Medical Center, Philadelphia, PA
VA Office of Research and Development
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP